The antipsychotic potential of cannabidiol: clinical implications for patients with psychosis and comorbid cannabis use disorder

摘要

A 22-year-old man is starting out-patient follow-up for a first episode of psychosis (FEP) that started in the context of a severe cannabis use disorder. The patient initially required 3 months of hospitalization and was stabilized with paliperidone. He accepted being switched to the long-acting injectable form and was discharged on paliperidone palmitate 150 mg, to be administered intramuscularly every 21 days.